Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CryoCath pivotal trial delayed

This article was originally published in The Gray Sheet

Executive Summary

FDA is requiring CryoCath to enroll 15 additional patients in its feasibility study for the Arctic Front cryoablation system to treat atrial fibrillation in order to assess design changes made to the catheter, firm announces April 3. The 15 additional patients have been identified and will be enrolled at two additional U.S. sites, accord-ing to CryoCath. Still, the pivotal stage of the STOP-AF trial, originally anticipated to begin in the second quarter, will likely be pushed back. Principle investigator Douglas Packer, MD, Mayo Clinic, announced in January that 13 of the initial 15 patients in the feasibility study were free of atrial fibrillation at three months (1"The Gray Sheet" Jan. 23, 2005, p. 9)...

You may also be interested in...

CryoCath’s Arctic Front for atrial fibrillation

Pivotal stage of the STOP AF trial assessing CryoCath's Arctic Front cryo-balloon catheter for treating atrial fibrillation gains conditional FDA investigational device exemption. Patient enrollment will begin within "weeks," the firm says Sept. 5. The randomized, five-center study will include 75 highly symptomatic paroxysmal AF patients who have failed at least one anti-arrhythmic drug, and will compare Arctic Front treatment with standard drug therapy. The trial's primary endpoint will be absence of AF at 12-month follow-up. Originally expected to begin in Q2, the trial has been delayed by device design changes (1"The Gray Sheet" April 10, 2006, In Brief)...

Top Electrophysiologists Assess AF Balloon Ablation Devices

Atrial fibrillation balloon ablation devices could benefit from a fundamental design change, proposed leading AF ablation electrophysiologists at the Boston AF Symposium Jan. 14

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts